New Development Programs to Include Response Prediction to Ovarian Cancer
Treatment, Predicting Risk of Gastric Cancer Recurrence, and
Differentiation of Small Cell From Non-Small Cell Lung Cancer In Addition, the Company has Identified Unique microRNA Biomarkers in the Serum of Colon Cancer Patients, Which may Serve as the Basis for a Future
Test for Colon Cancer New Tests Expected to be Developed and Marketed Through the Company's Clinical Laboratory Improvement Act (CLIA) Certified Laboratory, for Which
a Binding Acquisition Term Sheet has Recently Been Signed
REHOVOT, Israel and JERSEY CITY, New Jersey, June 18 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq: ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today the advancement of three new diagnostic tests into its development pipeline. The Company expects to develop and market the new tests through its own CLIA-certified laboratory, for which the Company recently signed a binding acquisition term sheet.
"We aim to be the leading high-complexity molecular diagnostics company, and we believe we have fine-tuned our product engine. This engine is now capable of producing a stream of products that answer unmet medical needs," said Amir Avniel, CEO and President of Rosetta Genomics. "We believe that by the end of 2009, we will have established a prominent position in the oncology and women's health fields."
Leveraging unique microRNA biomarkers identified using Rosetta
Genomics' proprietary microRNA extraction and quantification methods, the
new programs will focus on the following indications, which are expected to
be clinically available during 2009-201
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved